Paul Truex
is President and CEO of Anthera Pharmaceticals. Prior to founding Anthera‚ Mr. Truex served as a Director‚ President and CEO of Peninsula Pharmaceuticals where he raised over $81 million of institutional capital (including $21‚000‚000 from a key strategic partner) and negotiated both of Peninsula's product agreements with Shionogi & Co.‚ Ltd. and Takeda Chemical Industries. Peninsula was acquired by Johnson and Johnson during April of 2005 for $245 Million in an all cash transaction.
Prior to Peninsula‚ Mr. Truex was Vice President of Commercial Development for Versicor Inc. (subsequently Vicuron which was acquired by Pfizer) where he directed early commercial efforts for their infectious disease products and assisted with the company's successful IPO. Before Versicor‚ he worked at Eli Lilly and Company where he served in various marketing and sales roles during the launch of three different products for the primary care physician market (Actos®‚ Evista®‚ and Humalog 75/25®). He obtained his M.B.A. in Marketing and Finance from Indiana University and a B.A. Degree in International Economics from the University of Waterloo.